載入...
mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy
BACKGROUND: Tyrosine kinase inhibitors (TKIs) that act against the epithelial growth factor receptor (EGFR) were once widely used in chemotherapy for many human cancers. However, acquired chemoresistance occurred in almost all patients, limiting the clinical application of EGFR-TKI. Thus far, no eff...
Na minha lista:
| 發表在: | J Nanobiotechnology |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628454/ https://ncbi.nlm.nih.gov/pubmed/28978341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12951-017-0302-5 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|